Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits

Nitric oxide (NO) is the mediator of ischemic preconditioning against myocardial infarction. Desflurane produces anesthetic preconditioning to protect the myocardium against infarction. In the model of myocardial ischemia-reperfusion injury in rabbits, we evaluated desflurane-induced ischemic precon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Life sciences (1973) 2004-12, Vol.76 (6), p.651-660
Hauptverfasser: Tsai, Shen-Kou, Lin, Su-Man, Huang, Cheng-Hsiung, Hung, Wei-Chih, Chih, Chun-Lien, Huang, Shiang-Suo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 660
container_issue 6
container_start_page 651
container_title Life sciences (1973)
container_volume 76
creator Tsai, Shen-Kou
Lin, Su-Man
Huang, Cheng-Hsiung
Hung, Wei-Chih
Chih, Chun-Lien
Huang, Shiang-Suo
description Nitric oxide (NO) is the mediator of ischemic preconditioning against myocardial infarction. Desflurane produces anesthetic preconditioning to protect the myocardium against infarction. In the model of myocardial ischemia-reperfusion injury in rabbits, we evaluated desflurane-induced ischemic preconditioning and studied its mechanism of NO synthesis. Thirty-two male adult New Zealand white rabbits were anesthetized with intravenous (IV) 30 mg/kg pentobarbital followed by 5 mg/kg/hr infusion. All rabbits were subjected to 30 minutes (min) long lasting left anterior descending coronary artery (LAD) occlusion and three hours (hr) of subsequent reperfusion. Before LAD occlusion, the rabbits were randomly allocated into four groups for preconditioning treatment (eight for each group). The control group did not receive any preconditioning treatment. The desflurane group received inhaled desflurane 1.0 MAC (minimal end-tidal alveolar concentration) for 30 min that was followed by a 15 min washout period. The L-NAME-desflurane group received L-NAME (N G-nitro-L-arginine methyl ester; non-selective Nitric Oxide Synthetase (NOS) inhibitor) 1 mg/kg IV 15 min before 1.0 MAC inhaled desflurane for 30 min. The L-NAME group received L-NAME 1 mg/kg IV. Infarct volume, ventricular arrhythmia, plasma lactate dehydrogenase (LDH), creatine kinase (CK) activity and myocardial perfusion were recorded simultaneously. We have found that hemodynamic values of the coronary blood flow before, during, and after LAD occlusion were not significantly different among these four groups. For the myocardial ischemia-reperfusion injury animals, the infarction size (mean ± SEM) in the desflurane group was significantly reduced to 18 ± 3% in the area at risk as compared with 42 ± 7% in the control group, 35 ± 6 in the L-NAME group, and 34 ± 4% in the L-NAME-desflurane group. The plasma LDH, CK levels, and duration of ventricular arrhythmia were also significantly decreased in the desflurane group during ischemia-reperfusion injury. Our results indicate that desflurane is an anesthetic preconditioning agent, which could protect the myocardium against the ischemia-reperfusion injury. This beneficial effect of desflurane on the ischemic preconditioning is probably through NO release since L-NAME abrogates the desflurane preconditioning effect.
doi_str_mv 10.1016/j.lfs.2004.05.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67135619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320504006939</els_id><sourcerecordid>67135619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-7a2e3821a5762b4f3795457800cd8e1bb1a4cb957cfebe9531187031b5852ddf3</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7ri7P8CL5OSt20qnqz_wJMvuKix40XPIR0Uz9CRj0u3HvzfDDHgTApXDUy_1Poy9FtAKEMO7fbv40nYAfQvYQofP2E5M49zAIMVztgPo-kZ2gFfsVSl7AEAc5Ut2JRCHUcywY_Hee7IrT547Kn7Zso7UhOg2S44fM9kUXVhDiiF-4z4tS_p1-oViv9Mh6CbTkbLfSiV4fTGsOViefgdHPNNCuhAPkWdtTFjLDXvh9VLo9jKv2deH-y93H5unz4-f7j48NbYXuDaj7khOndA4Dp3pvRxn7HGcAKybSBgjdG_NjKP1ZGhGKWptkMLghJ1zXl6zt-fcY04_NiqrOtSLaVlqu7QVVdtLHMRcQXEGbU6lZPLqmMNB5z9KgDpJVntVJauTZAWoquS68-YSvpkDuX8bF6sVeH8GqFb8GSirYgPFajRUoatyKfwn_i9v247a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67135619</pqid></control><display><type>article</type><title>Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Tsai, Shen-Kou ; Lin, Su-Man ; Huang, Cheng-Hsiung ; Hung, Wei-Chih ; Chih, Chun-Lien ; Huang, Shiang-Suo</creator><creatorcontrib>Tsai, Shen-Kou ; Lin, Su-Man ; Huang, Cheng-Hsiung ; Hung, Wei-Chih ; Chih, Chun-Lien ; Huang, Shiang-Suo</creatorcontrib><description>Nitric oxide (NO) is the mediator of ischemic preconditioning against myocardial infarction. Desflurane produces anesthetic preconditioning to protect the myocardium against infarction. In the model of myocardial ischemia-reperfusion injury in rabbits, we evaluated desflurane-induced ischemic preconditioning and studied its mechanism of NO synthesis. Thirty-two male adult New Zealand white rabbits were anesthetized with intravenous (IV) 30 mg/kg pentobarbital followed by 5 mg/kg/hr infusion. All rabbits were subjected to 30 minutes (min) long lasting left anterior descending coronary artery (LAD) occlusion and three hours (hr) of subsequent reperfusion. Before LAD occlusion, the rabbits were randomly allocated into four groups for preconditioning treatment (eight for each group). The control group did not receive any preconditioning treatment. The desflurane group received inhaled desflurane 1.0 MAC (minimal end-tidal alveolar concentration) for 30 min that was followed by a 15 min washout period. The L-NAME-desflurane group received L-NAME (N G-nitro-L-arginine methyl ester; non-selective Nitric Oxide Synthetase (NOS) inhibitor) 1 mg/kg IV 15 min before 1.0 MAC inhaled desflurane for 30 min. The L-NAME group received L-NAME 1 mg/kg IV. Infarct volume, ventricular arrhythmia, plasma lactate dehydrogenase (LDH), creatine kinase (CK) activity and myocardial perfusion were recorded simultaneously. We have found that hemodynamic values of the coronary blood flow before, during, and after LAD occlusion were not significantly different among these four groups. For the myocardial ischemia-reperfusion injury animals, the infarction size (mean ± SEM) in the desflurane group was significantly reduced to 18 ± 3% in the area at risk as compared with 42 ± 7% in the control group, 35 ± 6 in the L-NAME group, and 34 ± 4% in the L-NAME-desflurane group. The plasma LDH, CK levels, and duration of ventricular arrhythmia were also significantly decreased in the desflurane group during ischemia-reperfusion injury. Our results indicate that desflurane is an anesthetic preconditioning agent, which could protect the myocardium against the ischemia-reperfusion injury. This beneficial effect of desflurane on the ischemic preconditioning is probably through NO release since L-NAME abrogates the desflurane preconditioning effect.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2004.05.025</identifier><identifier>PMID: 15567190</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Anesthetics ; Anesthetics, Inhalation - pharmacology ; Animals ; Creatine Kinase - metabolism ; Enzyme Inhibitors - pharmacology ; Hemodynamics - drug effects ; Isoflurane - analogs &amp; derivatives ; Isoflurane - pharmacology ; L-Lactate Dehydrogenase - metabolism ; Male ; Myocardial infarction ; Myocardial Infarction - pathology ; Myocardial Infarction - prevention &amp; control ; Myocardial Reperfusion Injury - metabolism ; Myocardial Reperfusion Injury - prevention &amp; control ; Myocardium - pathology ; Neuroprotective Agents - pharmacology ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Nitric Oxide Synthase Type III ; Preconditioning ; Rabbits ; Tachycardia, Ventricular - prevention &amp; control ; Ventricular Fibrillation - pathology</subject><ispartof>Life sciences (1973), 2004-12, Vol.76 (6), p.651-660</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-7a2e3821a5762b4f3795457800cd8e1bb1a4cb957cfebe9531187031b5852ddf3</citedby><cites>FETCH-LOGICAL-c415t-7a2e3821a5762b4f3795457800cd8e1bb1a4cb957cfebe9531187031b5852ddf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lfs.2004.05.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15567190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsai, Shen-Kou</creatorcontrib><creatorcontrib>Lin, Su-Man</creatorcontrib><creatorcontrib>Huang, Cheng-Hsiung</creatorcontrib><creatorcontrib>Hung, Wei-Chih</creatorcontrib><creatorcontrib>Chih, Chun-Lien</creatorcontrib><creatorcontrib>Huang, Shiang-Suo</creatorcontrib><title>Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>Nitric oxide (NO) is the mediator of ischemic preconditioning against myocardial infarction. Desflurane produces anesthetic preconditioning to protect the myocardium against infarction. In the model of myocardial ischemia-reperfusion injury in rabbits, we evaluated desflurane-induced ischemic preconditioning and studied its mechanism of NO synthesis. Thirty-two male adult New Zealand white rabbits were anesthetized with intravenous (IV) 30 mg/kg pentobarbital followed by 5 mg/kg/hr infusion. All rabbits were subjected to 30 minutes (min) long lasting left anterior descending coronary artery (LAD) occlusion and three hours (hr) of subsequent reperfusion. Before LAD occlusion, the rabbits were randomly allocated into four groups for preconditioning treatment (eight for each group). The control group did not receive any preconditioning treatment. The desflurane group received inhaled desflurane 1.0 MAC (minimal end-tidal alveolar concentration) for 30 min that was followed by a 15 min washout period. The L-NAME-desflurane group received L-NAME (N G-nitro-L-arginine methyl ester; non-selective Nitric Oxide Synthetase (NOS) inhibitor) 1 mg/kg IV 15 min before 1.0 MAC inhaled desflurane for 30 min. The L-NAME group received L-NAME 1 mg/kg IV. Infarct volume, ventricular arrhythmia, plasma lactate dehydrogenase (LDH), creatine kinase (CK) activity and myocardial perfusion were recorded simultaneously. We have found that hemodynamic values of the coronary blood flow before, during, and after LAD occlusion were not significantly different among these four groups. For the myocardial ischemia-reperfusion injury animals, the infarction size (mean ± SEM) in the desflurane group was significantly reduced to 18 ± 3% in the area at risk as compared with 42 ± 7% in the control group, 35 ± 6 in the L-NAME group, and 34 ± 4% in the L-NAME-desflurane group. The plasma LDH, CK levels, and duration of ventricular arrhythmia were also significantly decreased in the desflurane group during ischemia-reperfusion injury. Our results indicate that desflurane is an anesthetic preconditioning agent, which could protect the myocardium against the ischemia-reperfusion injury. This beneficial effect of desflurane on the ischemic preconditioning is probably through NO release since L-NAME abrogates the desflurane preconditioning effect.</description><subject>Anesthetics</subject><subject>Anesthetics, Inhalation - pharmacology</subject><subject>Animals</subject><subject>Creatine Kinase - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Hemodynamics - drug effects</subject><subject>Isoflurane - analogs &amp; derivatives</subject><subject>Isoflurane - pharmacology</subject><subject>L-Lactate Dehydrogenase - metabolism</subject><subject>Male</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - pathology</subject><subject>Myocardial Infarction - prevention &amp; control</subject><subject>Myocardial Reperfusion Injury - metabolism</subject><subject>Myocardial Reperfusion Injury - prevention &amp; control</subject><subject>Myocardium - pathology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase Type III</subject><subject>Preconditioning</subject><subject>Rabbits</subject><subject>Tachycardia, Ventricular - prevention &amp; control</subject><subject>Ventricular Fibrillation - pathology</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo7ri7P8CL5OSt20qnqz_wJMvuKix40XPIR0Uz9CRj0u3HvzfDDHgTApXDUy_1Poy9FtAKEMO7fbv40nYAfQvYQofP2E5M49zAIMVztgPo-kZ2gFfsVSl7AEAc5Ut2JRCHUcywY_Hee7IrT547Kn7Zso7UhOg2S44fM9kUXVhDiiF-4z4tS_p1-oViv9Mh6CbTkbLfSiV4fTGsOViefgdHPNNCuhAPkWdtTFjLDXvh9VLo9jKv2deH-y93H5unz4-f7j48NbYXuDaj7khOndA4Dp3pvRxn7HGcAKybSBgjdG_NjKP1ZGhGKWptkMLghJ1zXl6zt-fcY04_NiqrOtSLaVlqu7QVVdtLHMRcQXEGbU6lZPLqmMNB5z9KgDpJVntVJauTZAWoquS68-YSvpkDuX8bF6sVeH8GqFb8GSirYgPFajRUoatyKfwn_i9v247a</recordid><startdate>20041224</startdate><enddate>20041224</enddate><creator>Tsai, Shen-Kou</creator><creator>Lin, Su-Man</creator><creator>Huang, Cheng-Hsiung</creator><creator>Hung, Wei-Chih</creator><creator>Chih, Chun-Lien</creator><creator>Huang, Shiang-Suo</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041224</creationdate><title>Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits</title><author>Tsai, Shen-Kou ; Lin, Su-Man ; Huang, Cheng-Hsiung ; Hung, Wei-Chih ; Chih, Chun-Lien ; Huang, Shiang-Suo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-7a2e3821a5762b4f3795457800cd8e1bb1a4cb957cfebe9531187031b5852ddf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anesthetics</topic><topic>Anesthetics, Inhalation - pharmacology</topic><topic>Animals</topic><topic>Creatine Kinase - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Hemodynamics - drug effects</topic><topic>Isoflurane - analogs &amp; derivatives</topic><topic>Isoflurane - pharmacology</topic><topic>L-Lactate Dehydrogenase - metabolism</topic><topic>Male</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - pathology</topic><topic>Myocardial Infarction - prevention &amp; control</topic><topic>Myocardial Reperfusion Injury - metabolism</topic><topic>Myocardial Reperfusion Injury - prevention &amp; control</topic><topic>Myocardium - pathology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase Type III</topic><topic>Preconditioning</topic><topic>Rabbits</topic><topic>Tachycardia, Ventricular - prevention &amp; control</topic><topic>Ventricular Fibrillation - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsai, Shen-Kou</creatorcontrib><creatorcontrib>Lin, Su-Man</creatorcontrib><creatorcontrib>Huang, Cheng-Hsiung</creatorcontrib><creatorcontrib>Hung, Wei-Chih</creatorcontrib><creatorcontrib>Chih, Chun-Lien</creatorcontrib><creatorcontrib>Huang, Shiang-Suo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsai, Shen-Kou</au><au>Lin, Su-Man</au><au>Huang, Cheng-Hsiung</au><au>Hung, Wei-Chih</au><au>Chih, Chun-Lien</au><au>Huang, Shiang-Suo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2004-12-24</date><risdate>2004</risdate><volume>76</volume><issue>6</issue><spage>651</spage><epage>660</epage><pages>651-660</pages><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>Nitric oxide (NO) is the mediator of ischemic preconditioning against myocardial infarction. Desflurane produces anesthetic preconditioning to protect the myocardium against infarction. In the model of myocardial ischemia-reperfusion injury in rabbits, we evaluated desflurane-induced ischemic preconditioning and studied its mechanism of NO synthesis. Thirty-two male adult New Zealand white rabbits were anesthetized with intravenous (IV) 30 mg/kg pentobarbital followed by 5 mg/kg/hr infusion. All rabbits were subjected to 30 minutes (min) long lasting left anterior descending coronary artery (LAD) occlusion and three hours (hr) of subsequent reperfusion. Before LAD occlusion, the rabbits were randomly allocated into four groups for preconditioning treatment (eight for each group). The control group did not receive any preconditioning treatment. The desflurane group received inhaled desflurane 1.0 MAC (minimal end-tidal alveolar concentration) for 30 min that was followed by a 15 min washout period. The L-NAME-desflurane group received L-NAME (N G-nitro-L-arginine methyl ester; non-selective Nitric Oxide Synthetase (NOS) inhibitor) 1 mg/kg IV 15 min before 1.0 MAC inhaled desflurane for 30 min. The L-NAME group received L-NAME 1 mg/kg IV. Infarct volume, ventricular arrhythmia, plasma lactate dehydrogenase (LDH), creatine kinase (CK) activity and myocardial perfusion were recorded simultaneously. We have found that hemodynamic values of the coronary blood flow before, during, and after LAD occlusion were not significantly different among these four groups. For the myocardial ischemia-reperfusion injury animals, the infarction size (mean ± SEM) in the desflurane group was significantly reduced to 18 ± 3% in the area at risk as compared with 42 ± 7% in the control group, 35 ± 6 in the L-NAME group, and 34 ± 4% in the L-NAME-desflurane group. The plasma LDH, CK levels, and duration of ventricular arrhythmia were also significantly decreased in the desflurane group during ischemia-reperfusion injury. Our results indicate that desflurane is an anesthetic preconditioning agent, which could protect the myocardium against the ischemia-reperfusion injury. This beneficial effect of desflurane on the ischemic preconditioning is probably through NO release since L-NAME abrogates the desflurane preconditioning effect.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>15567190</pmid><doi>10.1016/j.lfs.2004.05.025</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2004-12, Vol.76 (6), p.651-660
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_miscellaneous_67135619
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Anesthetics
Anesthetics, Inhalation - pharmacology
Animals
Creatine Kinase - metabolism
Enzyme Inhibitors - pharmacology
Hemodynamics - drug effects
Isoflurane - analogs & derivatives
Isoflurane - pharmacology
L-Lactate Dehydrogenase - metabolism
Male
Myocardial infarction
Myocardial Infarction - pathology
Myocardial Infarction - prevention & control
Myocardial Reperfusion Injury - metabolism
Myocardial Reperfusion Injury - prevention & control
Myocardium - pathology
Neuroprotective Agents - pharmacology
NG-Nitroarginine Methyl Ester - pharmacology
Nitric oxide
Nitric Oxide - metabolism
Nitric Oxide Synthase - antagonists & inhibitors
Nitric Oxide Synthase Type III
Preconditioning
Rabbits
Tachycardia, Ventricular - prevention & control
Ventricular Fibrillation - pathology
title Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A44%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20desflurane-induced%20preconditioning%20following%20ischemia-reperfusion%20on%20nitric%20oxide%20release%20in%20rabbits&rft.jtitle=Life%20sciences%20(1973)&rft.au=Tsai,%20Shen-Kou&rft.date=2004-12-24&rft.volume=76&rft.issue=6&rft.spage=651&rft.epage=660&rft.pages=651-660&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2004.05.025&rft_dat=%3Cproquest_cross%3E67135619%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67135619&rft_id=info:pmid/15567190&rft_els_id=S0024320504006939&rfr_iscdi=true